28th April 2016, London, UK: OBN - the membership organisation supporting the UK’s emerging life sciences companies, announces today that the winner of the Perfect Pitch Competition, taking place at BioTrinity its annual conference in London for the first time on 27th April 2016, was Elasmogen Ltd. This fast-paced, interactive and lively session saw nine emerging UK R&D companies pitch in front of a panel of seasoned investors including:
• Kate Bingham, Managing Partner, SV Life Sciences
• Maina Bhaman, Director of Healthcare Investments, Imperial Innovations
• David Phillips, Partner, SR One
• Graeme Martin, President & CEO, Takeda Ventures Inc.
• Naveed Siddiqi, Partner, EdRIP
• Detlev Mennerich, Investment Manager, Boehringer Ingelheim Ventures
The judges selected Elasmogen to win the coveted Perfect Pitch winner’s certificate which also included a 30-munite masterclass with the host and panel members. Dr Caroline Barelle, CEO of Elasmogen, presented in a three minute pitch on their proprietary soloMER? technology that exploits the power of biologics as drugs but in a small (1/12 the size of an antibody), stable format that enables site specific delivery through complex and challenging environments like the eye and gut.
Kate Bingham, Managing Partner at SV Life Sciences and Chair of the Perfect Pitch session, said “Elasmogen was selected based on its confidence, style and pitch. All the judges were very impressed by Caroline as well as the other contestants. The passion and energy they all brought to communicating their vision for their business was only surpassed by the quality of their science. Hopefully the relationships they have made during BioTrinity will help them successfully advance their products and innovations.”
John Harris, CEO of OBN, commented, “We applaud the talented individuals that competed in this challenge and the high quality of their pitches. This competition, the first organised at BioTrinity, aims to put these emerging UK life sciences companies on the right track to move their innovation forward.”
The ten companies, that presented their innovation included:
Alfacyte, BeamLine Diagnostics, Curileum Discovery, DJS Antibodies, Elasmogen, NALIA Systems, NeRRe Therapeutics, Ryboquin Company and Somanautix.
